natgillin/translations-raw huggingface dataset:
8203 AA Lelystad Nederlandene
8203 AA Lelystad The Netherlands
82166 Graefelfing TYSKLAND
82166 Graefelfing GERMANY
8221 RA Lelystad Holland
8221 RA Lelystad The NETHERLANDS
8243 PZ Lelystad Nederlandene
8243 PZ Lelystad The Netherlands
83 (76; 89)
OBT (N = 237)
83 (76; 89)
Sensitivity score (GSS) §
83 IU/ml efter rekonstitution)
83 IU/mL after reconstitution)
83% (10/12)
with Q80K
83,3 % (p = 0,010)*
83.3 % (p=0.010)
83,3 % (p = 0,010)*
83.3% (p=0.010)
83,3% (80, 87) i henholdsvis de randomiserede Glivec- og IFN+Ara-C-grupper (p=0,073, log-rank test).
83.3% (80, 87) in the randomised Glivec and the IFN+Ara-C groups, respectively (p=0.073, log-rank test).
83,3% (80, 87) i henholdsvis de randomiserede imatinib- og IFN+Ara-C-grupper (p=0,073, log-rank test).
83.3% (80, 87) in the randomised imatinib and the IFN+Ara-C groups, respectively (p=0.073, log-rank test).
83,3% (p = 0,010)*
83.3% (p=0.010)
83,4 (±16,5) g/ml.
83.4 (± 16.5) g/mL.
83,5 %); Anæmi (G3/4:
Anaemia (G3/4: 12.4%)
83,5 %); Anæmi (G3/4:
Anaemia (G3/4: 12.4%);
84 (2 x 42 x 1) kapsler (enkeltdosis) (multipakning)
84 (2 x 42 x 1) capsules (unit dose) (multipack)
84 (2 x 42) breve (multipakning)
84 (2 x 42) sachets (multipack)
84 (2 x 42) depotplastre (multipakning)
84 (2 x 42) patches (multipack)
84 (2 x 42) kapsler (multipakning)
84 (2 x 42) capsules
84 (3 hylstre med 28) filmovertrukne tabletter 98 (7 hylstre med 14) filmovertrukne tabletter 10x1 filmovertrukne tabletter
84 (3 wallets of 28) film-coated tablets 98 (7 wallets of 14) film-coated tablets 10x1 film-coated tablet
84 (3 x 28 kapsler)
84 (3 x 28 capsules)
84 (3 x 28) filmovertrukne tabletter
84 (3 x 28) film-coated tablets
84 (3 x 28) tabletter (mulitpakning)
84 (3 x 28) tablets (multipack)
84 (3 x 28) tabletter (multipakning)
84 (3 x 28) tablets (multipack)
84 (3x28) tabletter
84 (3x28) tablets
84 (3x28) tabletter (multipakning)
84 (3x28) tablets (multipack)
84 depotplastre
84 patches
84 depottabletter
84 prolonged-release tablets
84 filmovertrukne tabletter
84 fim-coated tablets
84 filmovertrukne tabletter (kalenderpakning)
84 film-coated tablets (calendar blister)
84 filmovertrukne tabletter i PVC/Aclar/PVC Aluminiumsblistre i kartonæsker
EU/1/10/642/002 84 film-coated tablets in PVC/Aclar/PVC – Aluminium blisters in cardboard boxes
84 filmovertrukne tabletter.
84 film-coated tablets
84 hætteglas + 88 ampuller +
84 vials + 88 ampoules +
84 hætteglas til engangsbrug
84 single-use vials
84 kapsler
84 hard capsules
84 kapsler (4 blisterkort med 21 x 20 mg) (60 mg/dag dosis som forsyning til 28 dage)
84 capsules (4 blister cards of 21 x 20 mg) (60 mg/day dose for a 28 day supply)
84 kapsler (4 blisterkort med 21 x 20 mg) (60 mg/dag dosis)
84 capsules (4 blister cards of 21 x 20 mg) (60 mg/day dose)
84 mg (0,85 ml) to gange dagligt
84 mg (0.85 ml) twice daily
84 tabletten
84 tablets
84 tabletter
EU/1/12/755/015 [84 tablets]
84 tabletter
EU/1/12/755/024 [84 tablets]
84 tabletter
EU/1/12/756/015 [84 tablets]
84 tabletter
infusion
84 tabletter (72
84 tablets (72 active
84 tabletter: EU/1/08/480/005
84 tablets: EU/1/08/480/005
84 tabletter: EU/1/08/480/011
84 tablets: EU/1/08/480/011
84 tabletter: EU/1/08/480/017
84 tablets: EU/1/08/480/017
84 tabletter: EU/1/10/632/005
84 tablets: EU/1/10/632/005
84 tabletter: EU/1/10/632/012
84 tablets: EU/1/10/632/012
84 tabletter: EU/1/10/632/019
84 tablets: EU/1/10/632/019
84 tabletter: fire gennemsigtige kalender-blisters med 21 tabletter i hver
84 tablets: four transparent calendar blisters of 21 tablets each.
84 tyggetabletter
84 chewable tablets
84 x 1 filmovertrukne tabletter
84 x 1 film-coated tablets
84 x 1 hårde kapsler
84 x 1 hard capsules
84 x 1 kapsler
84 x 1 capsules (unit
84 x 1 kapsler (enkeltdosis)
84 x 1 capsules (unit
84 x 1 kapsler (enkeltdosis)
84 x 1 capsules (unit dose)
84 x 1 kapsler (enkeltdosis)
84 x1 capsules (unit dose)
84 x 1 tablet (enhedsdosis)
84 x 1 tablet (unit dose)
84 x 1 tablet (enkeltstyk)
84 x 1 tablet (unit dose)
84 X 1 tabletter
84 x 1 tablet
84 x 1 tabletter
84 x 1 tablets
84 x 1 tabletter (enhedsdosis)
84 x 1 tablets (unit dose)
84 x1 kapsler (enkeltdosis)
84 x1 capsules (unit dose)
84%) eller i det dobbelte immunosuppressive forsøg (78% vs.
84%) or the double immunosuppressant trial (78% Vs.
84,0 (75,8; 89,6)
N=119 91.4 (84.6, 95.3)
84,0 mikrogram
84.0 micrograms
84,3 (72,9 til 95,1)
84.3 (72.9 to 95.1)
84.496 forsøgspersoner i alderen 65 år og derover fik en enkelt vaccination med enten Prevenar 13 eller placebo efter randomisering 1:1.
84,496 subjects, 65 years and older received a single vaccination of either Prevenar 13 or placebo in a 1:1 randomization.
840 (20 x 42) tabletter
840 tablets (20 x 42 tablets)
840 tabletter (20 x 42 tabletter)
840 tablets (20 x 42 tablets)
84x1 kapsler (Enkeltdosisblister)
84x1 capsules (unit dose)
85 %
N/A
85 mg én gang dagligt
85 mg once daily
85 mg/m2 intravenøs
85 mg/m2 intravenous
85 mikrog /
85 mcg /
85 og 50 % af den administrerede radioaktivitet genfundet i urin, mens < 1 % blev genfundet i fæces.
14C-azacitidine, 85 and 50 % of the administered radioactivity was recovered in urine respectively, while < 1 % was recovered in faeces.
85 timer
85 hours
85,1 måneder
85.1 months
85,3 % til 97,8 %
85.3% to 97.8
85-90 % af den maksimale blodtrykssænkende effekt blev observeret efter 2 uger.
85 to 90% of the maximal blood- pressure-lowering effect was observed after 2 weeks.
850 mg enkeltdosis
850 mg single dose
8501 Novo mesto Slovenië
8501 Novo mesto Slovenia
852 mg cefovecin (som natriumsalt)
852 mg cefovecin (as sodium salt)
86,7 % (p = 0,015)*
86.7 % (p=0.015)
86,7 % (p = 0,015)*
86.7% (p=0.015)
86,7% (p = 0,015)*
86.7% (p=0.015)
86077 Pozzilli (IS) Italien
86077 Pozzilli (IS) Italy
866 behandlingsnaive voksne patienter til og med 96 ugers behandling (GS-US-292-0104 og GS-US-292-0111).
866 treatment-naïve adult patients through 96 weeks of treatment (GS-US-292-0104 and GS-US-292-0111).
87 % a patienterne havde tidligere modtaget antiretroviral behandling.
Eighty-seven percent of patients had received prior antiretroviral therapy.
87 % af de inkluderede patienter havde en ECOG-score på 0-1.
87% of patients enrolled had an ECOG performance status score of 0-1.
87 %]) for PHN-tilfælde og 50 % (95 % CI: [14 til 71 %]) for zoster-BOI.
[-10 to 87%]) for PHN incidence and 50% (95% CI: [14 to 71%]) for zoster BOI.
87 til 137
87 to 137
87,1 % (77,7, 92,6)f
87.1% (77.7, 92.6)f
87,1% (77,7; 92,6)f
87.1% (77.7, 92.6)f
87,6; 96,1
Prior pegIFN/RBV null 25/25
87,8 (353/402)
Treatment in combination with
87b [84-107]
87b [84, 107]
88 1 ml-ampuller med solvens til engangsbrug
88 single-use 1 ml ampoules of solvent
88 1 ml-ampuller med solvens til engangsbrug Denne pakning sælges ikke separat.
88 single-use 1 ml ampoules of solvent This pack is not to be sold separately.
88% (n = 93) af patienterne var i HIV-behandling, hyppigst med 2 NRTI’er + raltegravir.
Eighty-eight percent (n = 93) of the patients were on HIV therapy, most commonly with 2 NRTIs + raltegravir.
88% [78-93]
1st year of life
88,4 % (p = 0,002)*
88.4 % (p=0.002)
88,4 % (p = 0,002)*
88.4% (p=0.002)
88,4% (p = 0,002)*
88.4% (p=0.002)
88,6-96,4 %) i gruppen, der fik nilotinib 300 mg 2 gange dagligt, 92,2 % (95 % CI: 88,5-95,9 %) i gruppen, der fik nilotinib 400 mg 2 gange dagligt, og 88,0 % (95 % CI: 83,0-93,1 %) i gruppen, der fik imatinib 400 mg 1 gang dagligt.
88.6-96.4%) in the nilotinib 300 mg twice daily group, 92.2% (95% CI: 88.5-95.9%) in the nilotinib 400 mg twice daily group and 88.0% (95% CI: 83.0-93.1%) in the imatinib 400 mg once daily group.
88,6-96,4 %) i gruppen, der fik nilotinib 300 mg 2 gange dagligt, 92,2 % (95 % CI: 88,5-95,9 %) i gruppen, der fik nilotinib 400 mg 2 gange dagligt, og 88,0 % (95 % CI: 83,0-93,1 %) i gruppen, der fik imatinib 400 mg 1 gang dagligt.
88.6-96.4%) in the nilotinib 300 mg twice daily group, 92.2% (95% CI: 88.5-95.9%) in the nilotinib 400 mg twice daily group and 88.0% (95% CI: 84.2-94.0%) in the imatinib 400 mg once daily group.
88397 Biberach an der Riss Tyskland
D-88397 Biberach an der Riss Deutschland
88397 Biberach Tyskland
88397 Biberach Germany
89% (51/57) af de simeprevir-behandlede behandlingsnaive patienter og patienter med tidligere recidiv var egnede til en samlet behandlingsvarighed på 24 uger; hos disse patienter var SVR12-raten 94%.
Eighty-nine percent (51/57) of the simeprevir-treated treatment-naïve patients and prior relapsers were eligible for a total treatment duration of 24 weeks; in these patients the SVR12 rate was 94%.
89% af dosis udskilt inden for 10 dage, og henholdsvis 4% og 85% af radioaktiviteten kunne genfindes i urin og fæces.
[14C]-labelled dasatinib, approximately 89% of the dose was eliminated within 10 days, with 4% and 85% of the radioactivity recovered in the urine and faeces, respectively.
89% af patienterne havde diarré af maksimal grad 1 eller grad 211% af patienterne havde grad 3, ogen patient (<1%) havdeen grad 4-hændelse.
The maximum toxicity of diarrhoea was Grade 1 or 2 in 89% of patients, Grade 3 in 11% of patients; one patient (<1%) experienced a Grade 4 event.
89, rue de l'Institut B-1330 Rixensart Belgien
89, rue de l'Institut B-1330 Rixensart Belgium
89,0)
NA
89100 Sens Frankrig
89100 Sens France
89143 Blaubeuren Tyskland
89143 Blaubeuren, Germany
89143 Blaubeuren-Weiler Tyskland
89143 Blaubeuren-Weiler Germany
89257 Illertissen Tyskland
89257 Illertissen Germany
89d [82-95]
89d [82,95]
8Den gennemsnitlige HbA1c ændring er forskellen mellem saxagliptin+metformin og metformin grupperne.
8 Mean HbA1c change is the difference between the saxagliptin+metformin and metformin alone groups.
8I kontrollerede kliniske forsøg med aktive komparator var den gennemsnitlige vægtøgning 2-3 kg i løbet af et år med pioglitazon givet som monoterapi.
8 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2 - 3 kg over one year.
9 % af patienterne behandlet med Taltz udviklede neutropeni.
9% of patients receiving Taltz developed neutropenia.
9 - 17 år
9 - 17 years
9 - Undersøg nøje opløsningen.
9 - Examine the solution carefully.
9 cylinderampuller
9 cartridges
9 depotplastre
9 transdermal patches
9 EFT.
9 OJ No.
9 engangspenne
Route of Administration
9 forfyldte penne
9 pre-filled pens
9 gange om året).
9 times per year).
9 I kontrollerede kliniske forsøg med aktive stoffer som sammenligning var den gennemsnitlige vægtstigning med pioglitazon som monoterapi 2-3 kg i løbet af et år.
9 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2 – 3 kg over one year.
9 mg/kg 2 gange dagligt (højst 350 mg 2 gange dagligt)
9 mg/kg twice a day (a maximum dose of 350 mg twice daily)
9 mg/kg 2 gange dagligt (maksimalt 350 mg 2 gange dagligt.
9 mg/kg twice daily (a maximum dose of 350 mg twice daily)
9 mg/kg én gang hver 24. time
9 mg/kg once every 24 hours
9 mg/kg én gang hver 24. time indgivet over 60 minutter
9 mg/kg once every 24 hours infused over 60 minutes
9 mg/ml (0,9 %) natriumchlorid- injektionsvæske
Sodium chloride 9 mg/ml (0.9%) solution for injection
9 mg/ml (0,9 %) Natriumchloridinjektionsvæske
Sodium Chloride 9 mg/ml (0.9%)
9 mg/ml (0,9 %) natriumchloridinjektionsvæske
Sodium chloride 9 mg/ml (0.9%) solution for injection
9 ml Telzir oral suspension) 2 gange daglig i kombination med 100 mg ritonavir en gang daglig.
9 ml Telzir oral suspension) twice daily with 100 mg ritonavir once daily.
9 måneder, p = 0,01).
9 months, p = 0.01).
9 patienter (12%) gennemgik terapeutisk torakocentese.
Nine (12%) patients underwent therapeutic thoracentesis.
9 patienter responderede efter at have fået den indledende induktionsdosis, 16 patienter responderede ved uge 10.
9 patients responded after receiving the initial induction dose, 16 patients responded by week 10.
9 patienter, der blev behandlet med ofatumumab og chlorambucil, og 3 patienter, som blev behandlet med chlorambucil alene, havde sen debut af neutropeni, defineret som netropeni af grad 3 eller 4 med debut tidligst 42 dage efter den sidste behandling.
Nine patients treated with ofatumumab and chlorambucil, and three patients treated with chlorambucil alone had late onset neutropenia, defined as Grade 3 or 4 neutropenia starting at least 42 days after the last treatment.
9 penne
9 pre-filled pens
9 Penne
pens
9 percentil) og vægtpercentil (gennemsnitlig percentilreduktion på 13 percentil) blev observeret under behandling.
9 percentile) and weight percentile (mean percentile decrease of 13 percentile) were observed during treatment.
9 pipetter
9 pipettes
9 præ-definerede uønskede hændelseskategorier blev undersøgt (kardio- vaskulære tromboemboliske hændelser, hjertehindebetændelse, debut af eller forværring af kronisk hjerteinsufficiens, nedsat nyrefunktion/nyresvigt, øvre gastrointestinal kompliceret ulcus, større ikke- gastrointestinale blødninger, infektioner, ikke-infektiøse pulmonale komplikationer og død).
Nine pre-specified adverse event categories were evaluated (cardiovascular thromboembolic events, pericarditis, new onset or exacerbation of congestive heart failure, renal failure/dysfunction, upper GI ulcer complications, major non-GI bleeds, infections, non-infectious pulmonary complications, and death).
9 præ-definerede uønskede hændelseskategorier blev undersøgt (kardiovas- kulære tromboemboliske hændelser, hjertehindebetændelse, debut af eller forværring af kronisk hjerteinsufficiens, nedsat nyrefunktion/nyresvigt, øvre gastrointestinal kompliceret ulcus, større ikke- gastrointestinale blødninger, infektioner, ikke-infektiøse pulmonale komplikationer og død).
Nine pre-specified adverse event categories were evaluated (cardiovascular thromboembolic events, pericarditis, new onset or exacerbation of congestive heart failure, renal failure/dysfunction, upper GI ulcer complications, major non-GI bleeds, infections, non-infectious pulmonary complications, and death).
9 Quai Jules Guesde 94403 Vitry-sur-Seine Frankrig
9 Quai Jules Guesde 94403 Vitry-sur-Seine France
9 SÆRLIGE OPBEVARINGSBETINGELSER
9 SPECIAL STORAGE CONDITIONS
9 til 17 år
3 to 8 years
9 til 17 år
9 to 17 years
9 til < 16
9 to < 16
9 til <16
9 to < 16
9 timer efter applikation
9 hours after application
9 timer efter påføring
9 hours after application
9 timer.
9 hours.
9 ud af 11 patienter blev tilfredsstillende behandlet med posaconazol oral suspension 800 mg dagligt fordelt på flere doser i op til 377 dage med en median på 268 dage.
9 of 11 patients were successfully treated with posaconazole oral suspension 800 mg/day in divided doses for a median of 268 days and up to 377 days.
9 ud af 56 patienter var vedvarende positive (anti-vedolizumab antistof-positive ved 2 eller flere studiebesøg), og 33 patienter udviklede neutraliserende anti-vedolizumab antistoffer.
Nine out of 56 patients were persistently positive (anti-vedolizumab antibody-positive at two or more study visits) and 33 patients developed neutralizing anti-vedolizumab antibodies.
9 år efter vaccination var henholdsvis 94%, 96%, 99% og 60% anti-HPV 6-, anti-HPV 11-, anti-HPV 16- og anti-HPV 18-seropositive ved cLIA, og henholdsvis 98%, 96%, 100% og 91% var anti-HPV 6-, anti-HPV 11-, anti-HPV 16- og anti-HPV 18-seropositive ved IgG LIA.
Nine years after vaccination, 94%, 96%, 99% and 60% were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the cLIA, respectively, and 98%, 96%, 100% and 91% were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the IgG LIA, respectively.
9% (2-17%)
9% (2 to 17%)
9,0 % (-9,5 % til 27,5 %)
9.0% (-9.5% to 27.5%)
9,0 g/dag
9.0 g/day
9,0 mm, runde, normal konvekse, hvide, filmovertrukne tabletter mærket med ”OZ” over ”7,5” på den ene side og ”G” på den anden side.
9.0 mm, round, normal convex, white film-coated tablets debossed “OZ” over “7.5” on one side and “G” on the other side.
9,00 (3,97; 20,41) p<0,0001
9.00 (3.97, 20.41) p<0.0001
9,1 mm lange og 5,1 mm brede), bikonvekse, filmovertrukne tabletter med "TAK" og "ALG-12.5" trykt i gråt på den ene side.
5.1 mm wide), biconvex, film-coated tablets, with “TAK” and “ALG-12.5” printed in grey ink on one side.
9,1 mm lange og 5,1 mm brede), bikonvekse, filmovertrukne tabletter med "TAK" og "ALG-25" trykt i gråt på den ene side.
5.1 mm wide), biconvex, film-coated tablets, with “TAK” and “ALG-25” printed in grey ink on one side.
9,1 mm lange og 5,1 mm brede), bikonvekse, filmovertrukne tabletter med "TAK" og "ALG-6.25" trykt i gråt på den ene side.
5.1 mm wide), biconvex, film-coated tablets, with “TAK” and “ALG-6.25” on printed in grey ink on one side.
9,2 % p = 0,06.
9.2% p=0.06 respectively.
9,2 % p=0,06.
9.2% p=0.06 respectively.
9,3 x 19,1 mm i diameter og præget med Boehringer Ingelheims logo og V04.
19.1 mm, debossed with V04 on one side and the company symbol on the other side.
9,3% i placebo-gruppen).
9.3% on placebo).
9,4 (7,3-13,2) (4-ugers skema)
9.4 (7.3-13.2) (4-week schedule)
9,5 mg/24 timer
9.5 mg/24 h
9,5 mg/24 timer depotplaster
9.5 mg/24 h transdermal patch
9,5 mg/24 timer depotplaster rivastigmin
9.5 mg/24 h transdermal patch rivastigmine
9,5 mg/24 timer depotplaster).
9.5 mg/24 h transdermal patch).
9,5 mg/24 timer depotplastre meget let (21,8%), mildt (12,5%) eller moderat (6,5%) erytem eller meget let (11,9%), mild (7,3%) eller moderat (5,0%) kløe.
9.5 mg/24 h transdermal patches were very slight (21.8%), mild (12.5%) or moderate (6.5%) erythema or very slight (11.9%), mild (7.3%) or moderate (5.0%) pruritus.
9,5 mg/24 timer.
9.5 mg/24 h.
9,57 [3,39; 15,75]; P = 0,0026 c
9.57 [3.39, 15.75]; P = 0.0026 c
9,9-13,0 g/m2/dag til børn, som vejer mere end 20 kg, samt unge og voksne.
9.9 - 13.0 g/m2/day in children weighing more than 20 kg, adolescents and adults.
9,98 mg lactose (i form af monohydrat).
9.98 mg lactose(as monohydrate) in each 600 mg daily dose.
9,99 måneder (Hazard ratio 0,98), median progressionsfri overlevelsestid (PFS) 4,0 vs.
9.99 months (HR 0.98), median progression free survival time (PFS) 4.0 vs.
9- til 15-årige piger (Protokol 016 og 018)
9- to 15-Year-Old Girls (Protocols 016 and 018)
9-122
9 to 122
9-17 år
9 – 17 years
9-17 år
Common
9-17 år 3-8 år 6-35 måneder
9 – 17 years
9-17 år A/Vietnam A/Indonesia
9 – 17 years A/Vietnam A/Indonesia
9.000 IE/0,9 ml
9,000 IU/0.9 ml
9.000 mikrogram/ml for patienter under 2 år
9000 microgram (mcg/ml) for patients under 2 years of age
9.000 patienter, der blev behandlet i mindst 1 år.
9,000 patients treated for 1 year or more.
9.7 (8,3; NE)
9.7 (8.3, NE)
9.SÆRLIGE OPBEVARINGSBETINGELSER
SPECIAL STORAGE CONDITIONS
9/5 mmHg og 8/4 mmHg, og gennemsnitlig ekstra reduktioner i blodtryk i stående stilling på henholdsvis 6/6 mmHg, 11/4 mmHg og 4/5 mmHg.
9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were observed.
90 % af patienterne var CTCAE grad 0 ved baseline, og 10 % var CTCAE grad 1 ved baseline.
90% of patients were CTCAE grade 0 at baseline, and 10% were CTCAE grade 1 at baseline.
90 % konfidens- interval
90% Confidence Interval
90 (3 flasker med 30) filmovertrukne tabletter
90 (3 bottles of 30) film-coated tablets
90 (3 flasker med 30) filmovertrukne tabletter.
90 (3 bottles of 30) film-coated tablets
90 (3 flasker med 30) tabletter.
90 (3 bottles of 30) tablets.
90 (3 tabletbeholdere med 30) filmovertrukne tabletter
90 (3 bottles of 30) film-coated tablets
90 (3 tabletbeholdere med hver 30) filmovertrukne tabletter.
90 (3 bottles of 30) film-coated tablets
90 (3 x 30 x 1) kapsler (enkeltdosis) (multipakning) +
90 (3 x 30 x 1) capsules (unit dose) (multipack) +
90 (3 x 30) ampuller (multipakning)
90 (3 x 30) ampoules (multipack)
90 (3 x 30) AMPULLER MED 2 ML
90 (3 x 30) AMPOULES WITH 2 ML
90 (3 x 30) breve (multipaknin g)
90 (3 x 30) sachets (multipack)
90 (3 x 30) breve (multipakning)
90 (3 x 30) sachets (multipack)
90 (3 x 30) tabletter (multipakke)
90 (3 x 30) tablets (multipack)
90 (3x30) ampuller
90 (3x30) ampoules
90 (3x30) tabletter (multipakning)
90 (3x30) tablets (multipack)
90 (3x30x1) kapsler
90 (3x30x1) capsules (unit
90 ampuller
90 ampoules
90 AMPULLER MED 2 ML
90 AMPOULES WITH 2 ML
90 bløde kapsler
90 soft capsules
90 breve
90 pouches
90 comprimidos
90 tablets
90 depottabletter
90 tablets
90 enkeltdosis- beholdere
90 single-dose containers
90 enkeltdosisbeholdere
90 single-dose containers
90 filmovertrukne tabletter
90 tablets
90 hårde kapsler
90 hard capusles
90 Imatinib 400 mg 1 gang dagligt (n = 283)
90 Imatinib 400 mg once daily (n = 283)
90 kapsler
90 capsules
90 mg to gange dagligt
90 mg twice daily
90 mg/kg/dag (inkl. kardiovaskulære og nyre anomalier, såsom cordis ectopia og ectopiske nyrer og diafragma og umbilical brok) med fravær af maternel toksicitet.
6 mg/kg/day (including anophthalmia, agnathia, and hydrocephaly) and in rabbits at 90 mg/kg/day (including cardiovascular and renal anomalies, such as ectopia cordis and ectopic kidneys, and diaphragmatic and umbilical hernia), in the absence of maternal toxicity.
90 mikrog/0,5 ml
90 mcg/0.5 ml
90 minutter hver 3. uge givet 4 gange og efterfulgt af nivolumab 3 mg/kg som monoterapi hver 2. uge.
90 minutes administered intravenously every 3 weeks for the first 4 doses, followed by nivolumab 3 mg/kg as monotherapy every 2 weeks.
90 minutter.
90 minutes.
90 ml eller 100 ml*
90 ml or 100 ml
90 ml oral oplsøning
90 ml oral solution
90 ml oral opløsning
90 ml oral solution
90 ml/minut).
>90 ml/minute).
90 pakker
90 sachets
90 patienter randomiseret til placebo + BR krydsede over til at få IMBRUVICA efter IRC-bekræftet progression.
Ninety patients randomised to placebo + BR crossed over to receive IMBRUVICA following IRC confirmed progression.
90 smeltetabletter
90 orodispersible tablets
90 tabletten
90 tablets
90 tabletter
90 (3x30) tablets
90 tabletter
EU/1/12/755/016 [90 tablets]
90 tabletter
EU/1/12/755/025 [90 tablets]
90 tabletter
EU/1/12/756/016 [90 tablets]
90 tabletter (multipakning)
90 tablets (multipack)
90 tabletter (PVC/PCTFE blister)
90 tablets (PVC/PCTFE blisters)
90 tabletter: EU/1/08/469/004
90 tablets: EU/1/08/469/004
90 tabletter: EU/1/08/469/009
90 tablets: EU/1/08/469/009
90 tabletter: EU/1/08/469/014
90 tablets: EU/1/08/469/014
90 tabletter: EU/1/08/469/019
90 tablets: EU/1/08/469/019
90 tabletter: EU/1/08/469/024
90 tablets: EU/1/08/469/024
90 tabletter: EU/1/08/480/020
90 tablets: EU/1/08/480/020
90 tabletter: EU/1/10/632/006
90 tablets: EU/1/10/632/006
90 tabletter: EU/1/10/632/013
90 tablets: EU/1/10/632/013
90 tabletter: EU/1/10/632/020
90 tablets: EU/1/10/632/020
90 tabletter: EU/1/11/721/006
90 tablets: EU/1/11/721/006
90 tabletter: EU/1/11/721/013
90 tablets: EU/1/11/721/013
90 tabletter: EU/1/11/721/020
90 tablets: EU/1/11/721/020
90 tabletter: EU/1/11/723/006
90 tablets: EU/1/11/723/006
90 tabletter: EU/1/11/723/013
90 tablets: EU/1/11/723/013
90 tabletter: EU/1/11/723/020
90 tablets: EU/1/11/723/020
90 tabletter: fem gennemsigtige kalender-blisters med 18 tabletter i hver
90 tablets: five transparent blisters of 18 tablets each.
90 x 1 filmovertrukket tablet i hvide gennemsigtige PVC/PVdC-aluminium perforeret enkeltdosis- blisterpakninger.
EU/1/11/742/011 (90 x 1 – blister PVC/PVDC/alu)
90 x 1 filmovertrukket tablet; 9 blisterkort med 10 x 1 filmovertrukket tablet, hver i alu/alu- perforeret enkeltdosisblister.
90 x 1 film-coated tablet; 9 blister cards of 10 x 1 film-coated tablet each in Alu/Alu perforated unit dose blisters.
90 x 1 filmovertrukne tabletter
90 x 1 film-coated tablets
90 x 1 kapsler
90 x 1 capsules
90 x 1 tablet (enhedsdosis)
90 x 1 tablet (unit dose)
90 x 1 tablet (enkeltstyk)
90 x 1 tablet (unit dose)
90 x 1 tabletter
90 x 1 tablets
90 x 1 tabletter (enhedsdosis)
90 x 1 tablets (unit dose)
90 x 1 tabletter (enhedsdosis)
90x1 tablets (unit dose)
90 x 1 tabletter (enkeltdosis)
90 x 1 tablets (unit dose)
90 g FYLDT INJEKTIONSSPRØJTE
90 g PRE-FILLED SYRINGE
90 l 1 fyldt injektionssprøjte med påsat stempel uden nål
1 pre-filled syringe with pre-attached
90% af det absorberede aktive stof bliver udskilt via nyrerne.
90% of absorbed active substance is excreted through the kidneys.
90% af en 14C-mærket dosis udskilles via nyrerne og mindre end 2% via fæces.
90% of absorbed active substance is excreted through the kidneys.
90+ minutt er (ml/t)
90+ minutes (ml/hr)
90,5 dage
90.5 days
90,7 mg/g (4 mg/24 t)
90.7mg/g (4mg/24h)
90,75 kg
6 ' 0 ''